Erasca (ERAS) vs Ligand Pharmaceuticals (LGND)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Erasca (ERAS) has outperformed Ligand Pharmaceuticals (LGND) over the past year, gaining 536.2% versus a gain of 59.9%. Over five years, LGND leads with a +263.0% price change compared with -13.1% for ERAS. Ligand Pharmaceuticals is the larger company by market cap ($6.07 billion vs $5.57 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ERAS | LGND |
|---|---|---|
| Share price | $15.92 | $304.35 |
| Market cap | $5.57B | $6.07B |
| 1-day change | +2.94% | +3.17% |
| YTD return | +315.59% | +56.03% |
| 1-year return | +536.21% | +59.90% |
| 5-year return | -13.15% | +263.03% |
| P/E ratio (TTM) | — | 32.07 |
| Forward P/E | — | 25.47 |
| EPS (TTM) | $-0.95 | $9.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $268.09M |
| Revenue growth (YoY) | — | +60.40% |
| Net income (latest FY) | $-124.55M | $124.45M |
| Operating margin | — | 15.29% |
| Net margin | — | 46.42% |
| 52-week high | $24.28 | $326.63 |
| 52-week low | $2.11 | $175.89 |
| Distance from 52-week high | -34.45% | -6.82% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +51.49% | +13.11% |
| Average volume | 4.37M | 258.59K |
| Shares outstanding | 349.76M | 19.94M |
| Employees | 103 | 47 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ERAS has outperformed LGND by 476.3 percentage points over the past year.
About Erasca
ERAS stock →Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Ligand Pharmaceuticals
LGND stock →Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 47 employees
ERAS vs LGND FAQ
Which is bigger, Erasca or Ligand Pharmaceuticals?
Ligand Pharmaceuticals (LGND) is larger, with a market capitalization of $6.07B compared with $5.57B for Erasca (ERAS).
Which stock has performed better over the past year, ERAS or LGND?
ERAS returned +536.21% over the past 12 months, compared with +59.90% for LGND (price return, excluding dividends). Past performance does not predict future results.
Are Erasca and Ligand Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.